X-Linked Severe Combined Immunodeficiency Overview
Learn About X-Linked Severe Combined Immunodeficiency
X-linked severe combined immunodeficiency (SCID) is an inherited disorder of the immune system that occurs almost exclusively in males. Children with X-linked SCID are prone to recurrent and persistent infections because they lack the necessary immune cells to fight off certain bacteria, viruses, and fungi.
Variants (also known as mutations) in the IL2RG gene cause X-linked SCID. The IL2RG gene provides instructions for making a protein that is critical for normal immune system function. This protein is necessary for the growth and maturation of developing immune system cells called lymphocytes. Lymphocytes defend the body against potentially harmful invaders, make antibodies, and help regulate the entire immune system. Variants in the IL2RG gene prevent these cells from developing and functioning normally. Without functional lymphocytes, the body is unable to fight off infections.
X-linked SCID is the most common form of a group of severe combined immunodeficiency disorders. This group of disorders can be caused by variants in more than 20 genes. The incidence of all severe combined immunodeficiency disorders is 1 in 60,000 newborns and it is estimated that one-quarter to one-third of these cases are X-linked SCID.
This condition is inherited in an X-linked recessive pattern. The gene associated with this condition is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a variant would have to occur in both copies of the gene to cause the disorder. Because it is unlikely that females will have two altered copies of this gene, males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Robert Radin is an Allergy and Immunologist in Virginia Beach, Virginia. Dr. Radin and is rated as an Experienced provider by MediFind in the treatment of X-Linked Severe Combined Immunodeficiency. His top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), Hyperphenylalaninemia Due to Dehydratase Deficiency, and Complement Component 2 Deficiency.
Clinton Dunn is a Pediatric Allergy and Immunologist and a Pediatrics provider in Norfolk, Virginia. Dr. Dunn and is rated as an Experienced provider by MediFind in the treatment of X-Linked Severe Combined Immunodeficiency. His top areas of expertise are Severe Combined Immunodeficiency (SCID), X-Linked Severe Combined Immunodeficiency, Stridor, and Omenn Syndrome. Dr. Dunn is currently accepting new patients.
University Of Virginia Physicians Group
Larry Borish is an Allergy and Immunologist in Charlottesville, Virginia. Dr. Borish and is rated as an Experienced provider by MediFind in the treatment of X-Linked Severe Combined Immunodeficiency. His top areas of expertise are Common Variable Immune Deficiency, Hives, Primary Immunodeficiency (PID), and Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss Syndrome). Dr. Borish is currently accepting new patients.
Summary: This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) gene transfer treatment for X-linked severe combined immunodeficiency (XSCID, also known as SCID-X1) using a self-inactivating lentiviral vector incorporating additional features to improve safety and performance. The study will treat 35 patients with XSCID who are between 2 and 50 years of age and who have...
Summary: This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation. This may include inherited conditions, such as X-linked severe combined immunodeficiency (XSCID), chronic granulomatous disease (CGD), and leukocyte adhesion deficiency (LAD), or conditions resulting from outside factors, such as graft-versus-host disease (GVHD)....
Published Date: March 18, 2022
Published By: National Institutes of Health